TreAtments and outComes in paTients With prImary CutAneous Lymphoma (TACTICAL)

Peking University

Status: Enrolling

Conditions: Primary Cutaneous Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT05518851

PKU2022265

Details and patient eligibility

About

In order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in China, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for primary cutaneous lymphoma to systematically and effectively understand the current treatment status of patients with primary cutaneous lymphoma, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of primary cutaneous lymphoma and help patients with primary cutaneous lymphoma.

Full description

Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas presenting in the skin with no evidence of extracutaneous disease at the time of diagnosis. Primary cutaneous lymphomas include a heterogeneous group of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs). The different types of PCLs have highly characteristic clinical and histologic features, often a completely different clinical behavior and prognosis, and require a different type of treatment. Various studied in terms of the treatment and outcome of patients with different types of PCLs has been conducted in recent years. While the data of Chinese patients with PCLs are limited. Considering the different proportion of PCLs and limited treatment modalities in China, a nationwide multi-center prospective study is designed to summarize the current treatment status and outcome of patients.

Enrollment: 3,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases.
• Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy.

Exclusion criteria

• Patients who fail to provide informed consent form.
• Patients who cannot complete the questionnaire independently or under the guidance of investigators.